secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0000950170-23-007716
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics appoints Raju Prasad as CFO, replaces Brendan Smith
-----------------------------------------------------------------------

- Raju Prasad, Ph.D., appointed CFO effective March 14, 2023; previously Partner at William Blair.
- Annual salary $465,000, target bonus 45%, option grant for 100,000 shares, RSU grant for 40,000 shares.
- Brendan Smith resigned as CFO effective March 13, 2023; no disagreement on financial reporting.
- Smith remains employee through March 31, 2023, with continued equity vesting.
- Prasad receives $100,000 one-time payment, forfeitable if terminated for cause before March 14, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023007716/0000950170-23-007716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023007716/crsp-20230309.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer